Research Paper Volume 15, Issue 22 pp 13329—13344

circSLCO1B7 suppresses the malignant progression of hepatocellular carcinoma via the miR-556-3p/DAB2IP axis

class="figure-viewer-img"

Figure 5. circSLCO1B7 sponges miR-556-3p by targeting DAB2IP. (A) The binding sites between DAB2IP and miR-556-3p. (B) The luciferase activity of SK-HEP-1 and PLC/PRF/5 cells transfected with the WT or MUT sequence of DAB2IP and miR-556-3p mimic-NC or the mimic is shown. (C) qRT–PCR was used to detect the expression of DAB2IP in HCC tissues. (D) The survival analysis of DAB2IP was downloaded from Kaplan–Meier plotter (n = 364). (E) The expression of DAB2IP was positively related to circSLCO1B7 in HCC tissues and negatively related to miR-556-3p. (F, G) Western blot analysis of the protein levels of DAB2IP, E-cadherin, Vimentin and Snail in SK-HEP-1 and PLC/PRF/5 cells when circSLCO1B7 was overexpressed or knockdown. (H) Western blot analysis of the protein levels of DAB2IP in SK-HEP-1 and PLC/PRF/5 cells when miR-556-3p was overexpressed or knockdown. All data are presented as the means ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.